GLP-1 Medications Linked to Lower Fragility Fracture Risk in Type 2 Diabetes

An observational analysis of new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with new users of dipeptidyl-peptidase-4 (DPP-4) inhibitors found a 21 % lower risk of fragility fractures over a three-year period among patients with type 2 diabetes. The greatest risk reductions were observed for hip and femur fractures, which are among the most serious fracture types. Because the study design is observational, the association cannot be interpreted as proof that GLP-1 RAs directly prevent fractures.

HealthLine

Christopher D. Hamad, MD, a research fellow in orthopedic surgery at UCLA, noted that GLP-1 treatments may modulate inflammation and alter the balance between bone-forming and bone-resorbing cells, potentially offering protection against fragility fractures. David Cutler, MD, a family-medicine physician at Providence Saint John’s Health Center, cautioned that the lower fracture risk could stem from factors such as weight loss, improved diabetes control, or altered exercise patterns rather than a direct drug effect. He emphasized that laboratory data provide some support but that the study did not test mechanisms. Marc J. Levine, MD, FAAOS, chairman of orthopedic surgery at Hackensack Meridian Jersey Shore University Medical Center, explained that diabetes can decrease bone strength through disrupted bone turnover, making patients more prone to low-energy hip and spine fractures even when bone density appears normal on standard DEXA scans.

HealthLine

• 21 % reduction in overall fragility fracture incidence for GLP-1 RA users versus DPP-4 inhibitor users.

HealthLine

• Largest reductions observed in hip and femur fractures.

HealthLine

• Study period spanned three years and involved new users of each medication class.

HealthLine

Hamad highlighted the observational nature of the work and called the findings an “important signal” rather than definitive proof of bone protection. Cutler reiterated uncertainty about the causal pathway and announced ongoing translational studies to explore the mechanism. Levine stressed that diabetes-related changes in bone quality, not just bone density, underlie the heightened fracture risk in this population.

HealthLine

• “These injuries often require surgery and can lead to lasting loss of mobility and independence. Following a hip fracture, up to one-third of patients may die within the next year. However, this was an observational study, so the results should be viewed as an important signal rather than proof that GLP-1 RAs prevent fractures,” — Christopher D. Hamad

HealthLine

• “The finding was especially encouraging because the largest reductions were seen in hip and femur fractures, which can be devastating,” — Christopher D. Hamad

HealthLine

• “It may be because their diabetes is better controlled,” — Healthline. David Cutler

HealthLine

• “The effects of diabetes on bone can lead to [a] decrease in bone strength,” — Marc J. Levine

HealthLine